GB2484812A - Composition for reducing hair loss/improving hair condition - Google Patents
Composition for reducing hair loss/improving hair condition Download PDFInfo
- Publication number
- GB2484812A GB2484812A GB1118001.5A GB201118001A GB2484812A GB 2484812 A GB2484812 A GB 2484812A GB 201118001 A GB201118001 A GB 201118001A GB 2484812 A GB2484812 A GB 2484812A
- Authority
- GB
- United Kingdom
- Prior art keywords
- preparation
- hair
- extract
- vitamin
- hair loss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 24
- 208000024963 hair loss Diseases 0.000 title claims abstract description 23
- 230000003676 hair loss Effects 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title abstract description 5
- 230000003752 improving hair Effects 0.000 title description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 22
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 21
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 18
- VFLDPWHFBUODDF-FCXRPNKRSA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 17
- 230000003779 hair growth Effects 0.000 claims abstract description 15
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 14
- 239000010018 saw palmetto extract Substances 0.000 claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 12
- 229910052742 iron Inorganic materials 0.000 claims abstract description 11
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 11
- 235000012754 curcumin Nutrition 0.000 claims abstract description 9
- 229940109262 curcumin Drugs 0.000 claims abstract description 9
- 239000004148 curcumin Substances 0.000 claims abstract description 9
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 9
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960003080 taurine Drugs 0.000 claims abstract description 9
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000003719 hair strength Effects 0.000 claims abstract description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 8
- 229940016667 resveratrol Drugs 0.000 claims abstract description 8
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 8
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 8
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 7
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 7
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 7
- 229940063845 saw palmetto extract Drugs 0.000 claims abstract description 7
- 241000195955 Equisetum hyemale Species 0.000 claims abstract description 6
- 244000269722 Thea sinensis Species 0.000 claims abstract description 6
- 235000009569 green tea Nutrition 0.000 claims abstract description 6
- 210000000845 cartilage Anatomy 0.000 claims abstract description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 21
- 239000004615 ingredient Substances 0.000 claims description 17
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 11
- 229910052802 copper Inorganic materials 0.000 claims description 11
- 239000010949 copper Substances 0.000 claims description 11
- 239000011701 zinc Substances 0.000 claims description 11
- 229910052725 zinc Inorganic materials 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 239000004201 L-cysteine Substances 0.000 claims description 10
- 235000013878 L-cysteine Nutrition 0.000 claims description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 7
- 229940016409 methylsulfonylmethane Drugs 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 229940026310 caffeine 50 mg Drugs 0.000 claims description 3
- 229940031234 pine bark extract 50 mg Drugs 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 229940025991 beta sitosterol 200 mg Drugs 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 230000003760 hair shine Effects 0.000 claims description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract description 13
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract description 7
- 229960001948 caffeine Drugs 0.000 abstract description 7
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract description 7
- 229940076810 beta sitosterol Drugs 0.000 abstract description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 abstract description 4
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 abstract description 4
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 abstract description 4
- 229950005143 sitosterol Drugs 0.000 abstract description 4
- 229930003779 Vitamin B12 Natural products 0.000 abstract description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract description 3
- 235000019163 vitamin B12 Nutrition 0.000 abstract description 3
- 239000011715 vitamin B12 Substances 0.000 abstract description 3
- 229940106587 pine bark extract Drugs 0.000 abstract description 2
- 235000020741 pine bark extract Nutrition 0.000 abstract description 2
- 229960003284 iron Drugs 0.000 abstract 1
- 210000004209 hair Anatomy 0.000 description 19
- 235000015097 nutrients Nutrition 0.000 description 13
- 239000013589 supplement Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 7
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 7
- 240000006661 Serenoa repens Species 0.000 description 6
- 235000005318 Serenoa repens Nutrition 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229960001327 pyridoxal phosphate Drugs 0.000 description 3
- 235000008160 pyridoxine Nutrition 0.000 description 3
- 239000011677 pyridoxine Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000006749 inflammatory damage Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- -1 maltodextrose Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000021231 nutrient uptake Nutrition 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 244000139693 Arctostaphylos uva ursi Species 0.000 description 1
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 101100263202 Mus musculus Usp9x gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 241000200478 Prunus africana Species 0.000 description 1
- 235000000719 Prunus africana Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 229940032081 pine bark extract 30 mg Drugs 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An oral preparation for maintaining hair growth, strength and condition and reducing hair loss, comprising: - pine bark extract, - caffeine, - curcumin, - resveratrol - horsetail extract - L-cysteine - methylsulphonylmethane - biotin - vitamin B6 P5P - Zinc - Copper - Magnesium The composition may further comprise saw palmetto extract, beta sitosterol, green tea and taurine or iron, vitamin B12, marine cartilage and pantothenic acid.
Description
Complete Supplement Formulae for Maintenance of Hair Growth and Condition The present invention relates to a nutritional supplement for maintaining hair growth and the reduction of hair loss.
Nutrition is a complex subject as the effects of correct nutrition are indirect and slow to appear. This is particularly true for hair which is slow to respond to any form of treatment. Correct nutrition has been shown by many tri&s to be essential for healthy hair growth, and conversely many deficiencies correlate with hair loss. Hair nutrition is therefore a vital part of any treatment regime. A truly systematic and rigorous approach must be taken when formulating a nutritional supplement for hair due the many factors that affect the eventual efficacy of the treatment, The fact that hair growth requires complex nutrients and a ready supply of oxygen is well documented, but often overlooked. Perhaps because the effects are indirect and difficult to measure, comparatively few studies have triaUed ingredients and combinations of ingredients to maintain or promote hair growth.
t is not surprising then that many prior inventors of nutritional supplements have not considered the importance of bioavaUability, balancing elements with shared uptake pathways, and have fai'ed to ensure that no component has a negative effect on the absorption or action of other components in the formula.
Concentration There is a trend among supplement formulators, who are usually food scientists rather than pharmacologists, to include the maximum possib'e level of everything, "bigger is better". It is well known to pharmacologists who study absorption of substances into the body, that this is not necessarily correct. The most common example in hair supplements is saw palmetto. There is strong evidence from tissue sample experiments that saw palmetto inhibits the 5u reductase enzyme responsible for converting testosterone to dihydrotestosterone or "DHT"11. Component analysis shows that certain fatty acids but parUcularly lauric acid and oleic acki are responsible for the activity of saw palmetto121. Saw palmetto extract is a refined version of the whole fruit form, and retains a high percentage of the fatty acid content whilst removing other less useful components. Therefore it is apparent that a significantly lower dose of the extract is required to deliver the same levels of active fatty acids, one calculation estimates that 320mg of extract would have the fatty acid component of 1500mg of the whole fruit form.
An additional consideration is the selective inhibition of the two isoforms of 5o reductase. It has been shown in in vitro tests that both isoforms may be inhibited by lipid-rich saw palmetto extract?1, however there has been no study showing that the whole fruit form has a measurable effect on both isoforms. Of course the whole fruit contains all of the components of the extract and so theoretically would have the same effect, however this has not been proven.
Bloavailability Many common vitamins and all amino acids exist as multiple isomers, however it is rare that both or even all forms are equally available to human metabolism. The chirality of amino acids is well established, as is the dramatic difference between left and right enantiomers in the human body. On the whole, humans can only metabolise left or L enantiomers, such as L-Cysteine. R-Cysteine is not taken up or commonly metabolised, therefore commonly used racemic mixtures of the two forms are only half comprised of useful amino acids.
Vitamins, such as vitamin B6 also have several forms, pyridoxine is the form of vitamin B6 most commonly used in nutritional supplements, however it is not the bio-active form. Instead it must be phosphorylated to become pyridoxal 5 phosphate, which is active as an enzyme cofactor for many reactions, and is important for uptake of other nutrients as well. The phosphorylation reaction to activate pyridoxine takes energy and a certain set of conditions, and therefore not all the pyridoxine taken in a supplement is used. A more efficient alternative would be to use pyridoxal 5 phosphate in the supplement, so the bio-active form is immediately available, requiring no energy, and minimal wastage.
Bioavailability is not just controUed by isomeric forms. Nutrient uptake is complex, and there are many surprising instances where one nutrient is dramatically affected either negatively or positively, by a completely different nutrient in the formula. Pyridoxal 5 phosphate increases L-cysteine incorporation into keratin51, therefore a combination of the two would be beneficial for hair strength. Also interesting are the studies showing that both green tea and saw palmetto inhibit the absorption of iron. Whilst the mechanism for this is not entirely described, it is thought to be due to the concentrations of tannic acids in both16. Tannic acid levels are not significantly reduced when they are used in their purified extract form.
Therefore a formula must be designed so not only are bioavailable forms used, but the whole formula is studied for negative interactions and targeted towards a particular concern.
Balance Unfortunately a formula containing all of the nutrients necessary without a single negative interaction is rarely possible. Therefore balance is essential, especially where nutrients compete for uptake via the same pathways.
Balance is not simply a matter of including every competing element at the same percentage. Certain nutrients will compete more successfully than others, and all elements for healthy hair are necessary at different levels. The ion uptake channel for copper, zinc and magnesium ions is a useful illustration as the balance between the three competing elements is fine, and taking too much of one will decrease the other two. It has been shown that copper, zinc, and magnesium separately are all important for hair growth. As well as their role in nutrition and enzyme action, Copper and zinc have also both been shown to inhibit So reductase, although zinc has only been proven to inhibit the type 1 isoform found in skin not hair 7'8k Magnesium deficiency has been shown to correlate with certain diffuse alopedas in women91, but the precise cause has not been established.
However it would not be correct to create a supplement with more copper, slightly less zinc, and lower magnesium content due to their relative importance. In fact as magnesium is required at higher levels around the body comparatively it should be included at a higher dose, followed by zinc, and then copper which is useful even at low levels.
Component Synergy Whilst competition is important, it is also vital to consider the opposite possibility in complex formulae. Combinations of nutrients may improve the results of the two nutrients separately, such as the combination of curcumin and resveratrol. Resveratrol has been extensively studied both as an anti.inflammatory and anti-angiogenic agent, however results have been limited. Curcumin has also not lived up to initial promise as an anti-inflammatory. However it has been shown that the two work synergistically in a cancer model1101 to decrease inflammation.
Correct synergy can even result in a measurable effect where neither ingredient was effective separately. L-cysteine and pantothenic acid can be useful as they are incorporated into keratin; pantothenic acid in particular is very common in the form of panthenol, the conditioning agent. A combination of the two has been suggested by in vitro tests to help increase hair repair and keratinocyte proliferation11'121 which the two individually do not.
There are also several obvious examples where two ingredients act together, and these should not be ignored. For instance it is well known that vitamin Bi 2 and iron are both necessary for erythrocyte formation, and hence oxygen circulation, so it is important that a supplement contain both to significantly help this process.
Circulation An often overlooked factor to consider is the circulation of oxygen and nutrients to the hair. Even a perfectly balanced supplement would not be effective if there was no blood flow to the hair. Many believe that several forms of hair oss are caused or exacerbated by a deficient blood supply to the hair follicle, and so it is possible that nutrients from a supplement could not reach the follicle in useful quantities. Therefore it may be beneficial to increase the circulation. This can be achieved through topical treatments that stimulate nitric oxide production or angiogenesis. However a simpler solution may be to include a stimulant like taurine or caffeine to increase bloodflow around the entire body.
The stimulatory effects of caffeine and taurine on nutrient uptake and metabolism may also be beneficial. An added consideration is the possible effect of caffeine upon DHT and hair loss. Caffeine has been shown by several studies to reduce hair loss caused by DHT, the in vivo studies were successful topically1. Taurine has also been shown by in vitro testing to protect the hair from TGFI3-1 induced apoptosi&141.
Gender and Causation Whilst an ideal supplement would alleviate all known causes of hair loss and improve hair condition uniformly on any consumer, due to the competition mentioned above, and other practical considerations such as the size of a tablet, this is not possible. Therefore the cause of hair loss must be considered, and as many likely causes targeted as possible.
For some, particularly men, DHT is a major cause of hair loss. There is a certain amount of inflammation and oxidative damage associated with this form of hair loss.
Therefore one possible aspect should aim to reduce DHT levels, prevent DHT from acting, and prevent inflammation and oxidative damage at the same time. Keratin components and other nutrients may be useful to prevent deficiencies and encourage natural growth.
For others, mostly women, DHT is less important. lt is more common for female hair loss to be caused by iron or another deficiency, although there are also inflammatory aspects to these types of hair loss as well. Therefore an alternative aspect would not focus on anti-DHT agents, (particularly as some prevent iron absorption) but would focus on mineral and keratin component supplementation with similar levels of anti-inflammatory and antioxidant molecules.
Statement of the lnvention
From the research above, a specific combination of ingredients has been selected from the plethora of available ingredients and combinations to give a holistic solution for a variety of causes of hair loss in men and women.
The core of the invention is: Pine bark extract rich in proanthocyanidins which promote hair growth for men and women. Other sources such as grape seed exist, but pine bark is preferred as having high proanthocyanidin levels, wide availability, and a very low allergic response rate.
Caffeine which increases ingredient circulation and prevents DHT from acting on the hair follicle. Particularly importantly for women it does this without changing hormone levels, unlike other options such as saw palmetto, uva ursi, pygeum africanum and others.
Curcumin & Resveratrol in combination have powerful anti-inflammatory and antioxidant effects and unlike many antioxidants such as ascorbic acid, remain stable for prolonged periods of time.
Horsetail extract is an antioxidant and also a source of silica, which helps create smoother hair.
L-cysteine is a vital amino acid for keratin formation, unlike many amino acids it also creates stronger hair through the increased number of disulphide bonds.
Methylsulfonylmethane is a source of sulphur which helps form stronger hair.
Methylsulfonylmethane is a preferred source of sulphur as it is more readily bioavailable than other organic sulphur sources like chondroitin.
Biotin is another key component of strong and smooth hair.
Vitamin B6 P5P increases the uptake of several nutrients such as L-cysteine and is the only active form of Vitamin B6, there are 6 other forms available.
Zinc, Copper and Magnesium will prevent deficiencies which can all cause hair loss.
Each has benefits for hair growth but all need to be taken together, as taking just one may reduce serum levels of the others.
In addition, the following ingredients may be considered to make a supplement more
suitable for men.
Saw palmetto extract is a well-supported DHT inhibitor for men, unlike the whole fruit form and many other "DHT inhibitors" the extract inhibits both forms of 5 alpha reductase.
Beta sitosterol is another anti-DHT ingredient, but as it may work in a subtly different way from saw palmetto the two would be more effective in combination. Beta sitosterol could be used in the form of avocado, wheat germ, or rice, but a purer phytosterol extract is preferred.
Green tea is not a preferred antioxidant or DHT inhibitor in a formulation for women because it blocks iron absorption, however in combination with other antioxidants and anti-DHT agents it would have an additional effect.
Taurine is a very useful addition for male hair loss specifically as it alleviates the effects of TOF-beta, a cytokine responsible for causing hair to fafl out. This cytokine is stimulated by DHT, and so using Taurine in combination with DHT inhibitors will provide a broader spectrum of protection.
Alternatively, the following ingredients may be considered to make a supplement more
suitable for women.
Iron & Vitamin B12 are extremely important as anaemia is a common cause of poor hair condition and hair loss in women. It is not as prevalent as in men. Whilst iron is more commonly given as a single supplement, the two should improve erythropoiesis in a synergistic fashion.
Pantothenic acid improves hair condition independently, and in combination with L-cysteine alleviates certain forms of alopecia common in women.
Marine cartilage has been regarded by other inventors simply as another source of sulphur, similar to methylsulfonylmethane, however more recent research shows it stimulates hair growth -which methylsulfonylmethane alone does not, therefore it is a beneficial addition to a female formula.
In one aspect, the invention provides a preparation for maintaining hair growth, strength and/or condition; and/or the reduction of hair loss. The preparation in this aspect comprises all of the ingredients in set "a" in combination with either of the ingredient sets "b" or c", yet not both "b" and "c": a) 50mg of pine bark extract 50mg of caffeine 50mg of curcumin 100mg of resveratrol 30mg of horsetail extract 100mg of L-cysteine 150mg of methylsulfonylmethane I mg of biotin 2.8mg of vitamin 86 P5P 30mg of zinc 4mg of copper 150mg of magnesium b) 320mg of saw palmetto extract 50mg of beta sitosterol 200mg of green tea 100mg of taurine c) 48mg of iron 1 2pg of vitamin 812 12mg of pantothenic acid 640mg of marine cartilage n a preferred embodiment, any one or more of the quantities may be varied by as much as -i-I-30%. In a more greatly preferred embodiment, any one or more of the quantities may be varied by as much as +1-20%.
n a second aspect, the invention provides a preparation for maintaining hair growth, strength and condition; and/or the reduction of hair loss. The preparation in this aspect comprises all of the ingredients: 320mg of saw palmetto extract 50mg of pine bark extract 50mg of beta sitosterol 50mg of caffeine (a'so promoting circulation) 200mg of green tea (also an anti-oxidant) 50mg of curcumin (in combination with resveratroi) 100mg of resveratrol (in combination with curcumin) 30mg of horsetail extract (also a source of silica) 100mg of L-cysteine 150mg of methylsulfonylmethane I mg of biotin 2.8mg of vitamin B6 P5P 100mg of taurine 30mg of zinc 4mg of copper 150mg of magnesium In a preferred embodiment, any one or more of the quantities may be varied by as much as +1-30%. in a more greatly preferred embodiment, any one or more of the quantities may be varied by as much as +1-20%.
In a third aspect, the invention provides a preparation for maintaining hair growth, strength and condition; and/or the reduction of hair loss. The preparation in this aspect comprises all of the ingredients: 48mg of iron I2pg of vitamin B12 640mg of marine cartilage 100mg of L-cysteine 12mg of pantothenic acid 150mg of methylsuifonylmethane 1 mg of biotin 100mg of horsetail extract 50mg of curcumin 100mg of resveratrol 2.8 mg of vitamin B6 P5P 50mg of caffeine 50mg of pine bark extract 30mg of zinc 4 mg of copper 150mg of magnesium In a preferred embodiment, any one or more of the quantities may be varied by as much as +1-30%. ln a more greatly preferred embodiment, any one or more of the quantities may be varied by as much as +1-20%.
In any of the above aspects, the preparation may be in the form of one or more tablets, Uquid, powder or encapsulated powder and may be taken orally. The preparation may be mixed with other powders or liquids prior to ingestion. The preparation may be taken as two or more parts at substantially different times of the day and/or night, and composition of each part may differ from the others.
The preparation may contain at least one inactive ingredient such as maltodextrose, magnesium stearate, silicon dioxide, microcrystalline cellulose, and/or stearic acid.
The preparation may have a therapeutic effect. The preparation may reduce or prevent the action of factors such as hormones which may promote hair loss. The preparation may be used as part of a programme to reduce hair loss, maintain or improve hair growth, and/or enhance hair strength, shine and condition. Programme in this case is accepted to mean either repeated use of this invention alone, or use of the invention in conjunction with other treatment options such as minoxidil, finasteride, dutasteride, spironolatone, ketoconazole, thymic peptides, copper peptides, growth factors, platelet rich plasma therapy, hair transplantation, restricted or planned diet, shampoos and/or conditioners. Any and all of these examples can be used in combination.
References 1. Marks L. S., et aL, Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology, 2001. 57(5): p. 999-1005.
2. Abe M., et al. Pharmacologically relevant receptor binding characteristics and 5alpha-reductase inhibitory activity of free Fatty acids contained in saw palmetto extracL Bbbgical and Pharmacological Bulletin, 2009. 32(4): p. 646-650.
3. lehló C., et aL Human prostatic steroid 5 alpha -reductase iso forms--a comparative study of selective inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 1995. 54(5-6): p.273-279.
4. Combs, G. F. The Vitamins: Fundamental Aspects in Nutrition and Health.
Elsevier, 2008.
5. D'Agostini F., et al., Chemoprevention of smoke-induced alopecia in mice by oral administration of L-cystine and vitamin 86. Journal of Dermatological Science, 2007. 46(3): p. 189-1 98.
6. Miller L.G., Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Archives of Internal Medicine, 1998. 158(20): p. 2200-2211.
7. Sugimoto Y., et al., Cations inhibit specifically type 15 alpha-reductase found in human skin. Journal of Investigative Dermatology, 1995. 104(5): p. 775-778.
8. Om A.S., Chung K.W., Dietary zinc deficiency alters 5 alpha-reduction and aromatization of testosterone and androgen and estrogen receptors in rat liver.
Journal of Nutrition,1996. 126(4): p. 842-848.
9. Tataru A., Nicoara E., Idiopathic diffuse alopecias in young women correlated with hypomagnesemia. Jorunal of the European Academy of Dermatology and Venereology, 2004. 18(3): p. 393-394.
10. Aftab N., Vieira A., Antioxidant activities of curcumin and combinations of this curcuminoid with other phytochemicals. Phytotherapy Research, 2010. 24(4): p. 500-502.
11. Budde J. et at. Systemic therapy of diffuse effluvium and hair structure damage.
Der Hautarzt, 1993. 44(6): p. 380384.
12. Obrigkeit D.H, et ak, Xenobiotics in vitro: the influence of L-cystine, pantothenat, and miliacin on metabolic and proliferative capacity of keratinocytes. Cutaneous and Ocular Toxicology, 2006. 25(1): p. 13-22.
13. Fischer T.W., et ak, Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro. International Journal of Dermatology, 2007. 46(1): p. 27-35.
14. Cottin C, et at., Protective effects of taurine on human hair follicle grown in vitro.
International Journal of Cosmetic Science, 2006. 28(4): p. 289-298.
Claims (12)
- Claims 1. A preparation to be taken orally for maintaining hair growth, strength and condition; and/or the reduction of hair loss consisting of the following ingredients: 50mg of pine bark extract 50mg of caffeine 50mg of curcumin 100mg of resveratrol 30mg of horsetail extract 100mg of L-cysteine 1 50mg of methylsulfonylmethane 1 mg of biotin 2.8mg of vitamin B6 P5P 30mg of zinc 4mg of copper 150mg of magnesium Any one or more of the quantities may be varied by approximately +1-20%.
- 2. The preparation of claim 1, further consisting of the following ingredients: 320mg of saw palmetto extract 50mg of beta sitosterol 200mg of green tea 100mg of taurine Any one or more of the quantities may be varied by approximately +/-20%.
- 3. A preparation of claim 1, further consisting of the following ingredients: 48mg of iron 1 2pg of vitamin 812 640mg of marine cartilage 12mg of pantothenic acid Any one or more of the quantities may be varied by approximately +1-20%.
- 4. The preparation of any of claims 1-3 wherein the preparation is in the form of one or more tablets to be taken orafly.
- 5. The preparation of any of ciaims 1-3 wherein the preparation is in the form of a powder to be taken orafly.
- 6. The preparation of claim 5 wherein the preparation in the form of a powder is encapsulated.
- 7. The preparation any of claims 1-3 wherein the preparation is in the form of a liquid to be taken orally.
- 8. The preparation of any of claims 6, 7 and 8 wherein the powder or liquid are mixed with other powders or liquids prior to ingestion.
- 9. The preparation of any of the above claims wherein the preparation is ingested in two or more parts at substantially different times of the day.
- 10. Use of the preparation of any of the above claims as part of a programme to reduce hair loss.
- 11. Use of the preparation of any of the above claims as part of a programme to maintain hair growth.
- 12. Use of the preparation of any of the above claims as part of a programme to maintain hair strength, shine and/or condition.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1017634.5A GB201017634D0 (en) | 2010-10-19 | 2010-10-19 | Nutritional supplement |
Publications (2)
Publication Number | Publication Date |
---|---|
GB201118001D0 GB201118001D0 (en) | 2011-11-30 |
GB2484812A true GB2484812A (en) | 2012-04-25 |
Family
ID=43334052
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1017634.5A Ceased GB201017634D0 (en) | 2010-10-19 | 2010-10-19 | Nutritional supplement |
GB1118001.5A Withdrawn GB2484812A (en) | 2010-10-19 | 2011-10-19 | Composition for reducing hair loss/improving hair condition |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1017634.5A Ceased GB201017634D0 (en) | 2010-10-19 | 2010-10-19 | Nutritional supplement |
Country Status (1)
Country | Link |
---|---|
GB (2) | GB201017634D0 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2436246A1 (en) * | 2013-09-06 | 2013-12-27 | Catalonia Nueva Corporación Empresarial, S.L. | Cosmetic composition for the care and treatment of alopecia (Machine-translation by Google Translate, not legally binding) |
ES2517741A1 (en) * | 2013-04-30 | 2014-11-03 | Lacer, S.A. | Composition to reduce and/or prevent hair loss and/or stimulate hair growth (Machine-translation by Google Translate, not legally binding) |
ITUB20160806A1 (en) * | 2016-02-17 | 2017-08-17 | Beautiful Aging Solutions Pte Ltd | COMPOSITION FOR THE PREVENTION AND TREATMENT OF PROBLEMS OF HAIR GROWTH |
EP3213747A1 (en) * | 2016-03-04 | 2017-09-06 | Laboratorio Reig Jofre S.A. | Tablets with a high-content of active ingredients useful for treating hair loss or stimulating its growth |
DE102017008429A1 (en) * | 2017-09-07 | 2019-03-07 | Dr. Theiss Naturwaren Gmbh | Means for hair treatment |
US10688037B1 (en) | 2015-12-31 | 2020-06-23 | Nutraceutical Wellness Inc. | Compositions and method for hair regrowth |
US10709659B1 (en) * | 2015-12-31 | 2020-07-14 | Nutraceutical Wellness Inc. | Composition and methods for hair regrowth |
EP4201418A1 (en) | 2021-12-23 | 2023-06-28 | ASC Regenity Ltd. | Hair care nutritional supplement composition |
WO2023133162A1 (en) * | 2022-01-04 | 2023-07-13 | Vias Partners, Llc | Compositions and methods for treating and preventing hair loss |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003063851A1 (en) * | 2002-02-01 | 2003-08-07 | Giuliani S.P.A. | Composition for pharmaceutical or dietetic use for combating hair loss |
CN1679502A (en) * | 2005-01-18 | 2005-10-12 | 王明彰 | Use of DL-cysteine or its salt in cosmetics preparation |
WO2006087759A2 (en) * | 2005-02-21 | 2006-08-24 | Safi Investment Holding Ag | Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field |
WO2009150421A2 (en) * | 2008-06-10 | 2009-12-17 | Robert Peter Taylor | Composition for the treatment of hair loss and baldness |
EP2158906A1 (en) * | 2008-08-28 | 2010-03-03 | ProxiPHARM GmbH | Composition for the treatment of alopecia |
EP2255782A1 (en) * | 2009-05-25 | 2010-12-01 | Keune Haircosmetics Manufacturing B.V. | Composition for the prevention or treatment of hair loss, and method of preparation |
US20110287061A1 (en) * | 2010-05-20 | 2011-11-24 | Cathy Beggan | Dietary composition and method for promoting healthy hair growth and melanogenesis |
-
2010
- 2010-10-19 GB GBGB1017634.5A patent/GB201017634D0/en not_active Ceased
-
2011
- 2011-10-19 GB GB1118001.5A patent/GB2484812A/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003063851A1 (en) * | 2002-02-01 | 2003-08-07 | Giuliani S.P.A. | Composition for pharmaceutical or dietetic use for combating hair loss |
CN1679502A (en) * | 2005-01-18 | 2005-10-12 | 王明彰 | Use of DL-cysteine or its salt in cosmetics preparation |
WO2006087759A2 (en) * | 2005-02-21 | 2006-08-24 | Safi Investment Holding Ag | Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field |
WO2009150421A2 (en) * | 2008-06-10 | 2009-12-17 | Robert Peter Taylor | Composition for the treatment of hair loss and baldness |
EP2158906A1 (en) * | 2008-08-28 | 2010-03-03 | ProxiPHARM GmbH | Composition for the treatment of alopecia |
EP2255782A1 (en) * | 2009-05-25 | 2010-12-01 | Keune Haircosmetics Manufacturing B.V. | Composition for the prevention or treatment of hair loss, and method of preparation |
US20110287061A1 (en) * | 2010-05-20 | 2011-11-24 | Cathy Beggan | Dietary composition and method for promoting healthy hair growth and melanogenesis |
Non-Patent Citations (1)
Title |
---|
WPI Abstract Accession No. 2006-146339 [16] & CN 1679502 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2517741A1 (en) * | 2013-04-30 | 2014-11-03 | Lacer, S.A. | Composition to reduce and/or prevent hair loss and/or stimulate hair growth (Machine-translation by Google Translate, not legally binding) |
ES2436246A1 (en) * | 2013-09-06 | 2013-12-27 | Catalonia Nueva Corporación Empresarial, S.L. | Cosmetic composition for the care and treatment of alopecia (Machine-translation by Google Translate, not legally binding) |
US10688037B1 (en) | 2015-12-31 | 2020-06-23 | Nutraceutical Wellness Inc. | Compositions and method for hair regrowth |
US10709659B1 (en) * | 2015-12-31 | 2020-07-14 | Nutraceutical Wellness Inc. | Composition and methods for hair regrowth |
US11213478B2 (en) | 2015-12-31 | 2022-01-04 | Nutraceutical Wellness Inc. | Compositions and methods for hair regrowth |
ITUB20160806A1 (en) * | 2016-02-17 | 2017-08-17 | Beautiful Aging Solutions Pte Ltd | COMPOSITION FOR THE PREVENTION AND TREATMENT OF PROBLEMS OF HAIR GROWTH |
EP3213747A1 (en) * | 2016-03-04 | 2017-09-06 | Laboratorio Reig Jofre S.A. | Tablets with a high-content of active ingredients useful for treating hair loss or stimulating its growth |
DE102017008429A1 (en) * | 2017-09-07 | 2019-03-07 | Dr. Theiss Naturwaren Gmbh | Means for hair treatment |
WO2019048326A1 (en) * | 2017-09-07 | 2019-03-14 | Dr. Theiss Naturwaren Gmbh | Hair treatment product |
EP4201418A1 (en) | 2021-12-23 | 2023-06-28 | ASC Regenity Ltd. | Hair care nutritional supplement composition |
WO2023118518A1 (en) | 2021-12-23 | 2023-06-29 | ASC REGENITY Limited | Hair care nutritional supplement composition |
WO2023133162A1 (en) * | 2022-01-04 | 2023-07-13 | Vias Partners, Llc | Compositions and methods for treating and preventing hair loss |
Also Published As
Publication number | Publication date |
---|---|
GB201118001D0 (en) | 2011-11-30 |
GB201017634D0 (en) | 2010-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2484812A (en) | Composition for reducing hair loss/improving hair condition | |
Hosking et al. | Complementary and alternative treatments for alopecia: a comprehensive review | |
KR101780692B1 (en) | Composition comprising natural mixture extract for preventing lose of hair or promoting growth of hair | |
US20120141611A1 (en) | Methods and compositions using ergothioneine to treat a variety of health related factors | |
AU2012213590B2 (en) | Cosmetic use | |
US20110287061A1 (en) | Dietary composition and method for promoting healthy hair growth and melanogenesis | |
Hajhashemi et al. | Beneficial effects of pumpkin seed oil as a topical hair growth promoting agent in a mice model | |
KR20070056207A (en) | Testosterone 5alpha-reductase inhibitor containing vitis radix extract | |
JP2021501206A (en) | Nutritional composition containing a source of vegetable fatty acids | |
KR20180100288A (en) | Composition for prevention of losing hair or promotion of growing hair | |
JP5769611B2 (en) | Hair restorer composition | |
US11850451B2 (en) | Cosmetic compositions and methods for improving skin conditions | |
Gasmi et al. | Natural Compounds Used for Treating Hair Loss | |
Presley et al. | A scoping review of pharmacotherapy, complementary, and alternative medicine (CAM), and surgical therapies for androgenic alopecia | |
EP2703003A1 (en) | A pomegranate extract and compositions containing pomegranate polyphenols for treating or preventing diseases or physiopathological conditions associated with an excessive gene expression and/or physiological activity of interleukin-6 | |
EP3568131B1 (en) | Composition comprising 7-hydroxymatairesinol for use in the treatment and in the prevention of trichological diseases of inflammatory and/or hormonal origin | |
TWI758437B (en) | Combination of aqueous extracts of watercress and of indian cress and atp in the treatment of alopecia | |
EP1317239B1 (en) | Synergetic combinations based on plants for treating hair loss | |
DE202007012586U1 (en) | Fenugreek seed extract | |
US20090098217A1 (en) | Compositions and methods for promoting thicker hair | |
Gul et al. | Effect of boron element on photoaging in rats | |
CN111713623A (en) | Solid beverage and preparation method thereof | |
US8580236B2 (en) | Hair sustaining formulation | |
Du et al. | Oxidative stress in hair follicle development and hair growth: Signalling pathways, intervening mechanisms and potential of natural antioxidants | |
Cobbledick | Microsoft word-hair nutrition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |